Catalyst
Slingshot members are tracking this event:
Crinetics Pharma's (CRNX) Phase 1 of CRN04894 to suppress ACTH-stimulated cortisol secretion for treatment of Cushing’s disease and congenital adrenal hyperplasia - Results expected in 1H 2021
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CRNX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 10, 2021
Occurred Source:
https://crinetics.com/crn04894-demonstrates-pharmacologic-proof-of-concept/
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Crn04894, Cushing’s Syndrome, Congenital Adrenal Hyperplasia
